A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

Novartis

Status and phase

Completed

Phase 2

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: vildagliptin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00238498

CLAF237A1202

Details and patient eligibility

About

This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of a number of doses of vildagliptin, an unapproved drug, in the treatment of people with type 2 diabetes.

Enrollment

291 patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of type 2 diabetes
Patients who have been placed on diet and exercise therapy without achievement of glycemic control
Outpatients

Exclusion criteria

Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
Significant cardiovascular diseases
Significant diabetic complications
Other protocol-defined exclusion criteria may apply